Cosmos Health Signs Agreement to Deploy Artificial Intelligence (AI)-Powered Call Center to Optimize Order Intake, Customer Communications, and Operating Efficiency
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) signed an agreement to deploy an AI-powered call center for its subsidiary CosmoFarm, supporting order intake and routine customer communications. The multilingual platform will automate inbound and outbound calls, integrate with back-end systems, and provide real-time reporting, targeting process optimization, cost efficiencies, and improved customer experience.
This move extends Cosmos Health’s broader AI strategy, launched in April 2026, which applies AI across front-end and back-end operations. According to Cosmos Health, AI-driven optimization may reduce certain operating expenses by up to 30%, depending on the process and automation level.
AI-generated analysis. Not financial advice.
Positive
- AI-powered call center automates order intake and routine support for CosmoFarm
- Multilingual, inbound/outbound platform integrates with back-end systems and dashboards
- Supports scaling CosmoFarm’s record quarterly revenue and growing transaction volumes
- Part of wider AI strategy across front-end and back-end operations
- Company targets up to 30% expense reduction in some AI-optimized processes
Negative
- None.
News Market Reaction – COSM
On the day this news was published, COSM declined 0.57%, reflecting a mild negative market reaction. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $75K from the company's valuation, bringing the market cap to $13.11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
COSM traded down about 0.8% with several medical distribution peers also negative (SNYR, ZYXI, YI, EDAP all down), suggesting today’s weakness aligns more with a broader sector pullback than AI‑specific news.
Previous Crypto,AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Shareholder letter | Positive | +2.1% | Outlined record FY2025 results and multi‑year growth and profitability targets. |
| Apr 16 | AI strategy update | Positive | +4.0% | Expanded AI integration across operations targeting up to 30% expense reductions. |
| Sep 29 | Strategic update | Positive | -0.9% | Announced $300M digital financing facility and strong wholesale revenue growth. |
| Feb 10 | AI cancer patents | Positive | +2.7% | Filed AI‑driven patents for glioma and hematologic malignancy treatments. |
| Feb 05 | AI MS patent | Positive | +0.8% | Filed AI‑driven patent for multiple sclerosis treatment targeting large market. |
AI/crypto‑tagged announcements for COSM have usually produced modest positive price reactions, with one notable negative divergence.
Historical Comparison
In prior crypto/AI‑tagged updates, COSM has typically seen modest gains, averaging about 1.74% moves, suggesting investors often react constructively to AI and digital‑strategy disclosures when fundamentals support them.
Same‑tag history shows a progression from AI‑driven R&D patents to broad AI operational integration and financing structures, with this call‑center deployment extending that efficiency‑focused AI rollout into customer communications.
Regulatory & Risk Context
Reported short interest appears relatively low, implying limited short‑squeeze potential but also suggesting volatility will be driven more by fundamentals and liquidity than by forced covering.
An effective S-3 shelf for up to $200,000,000 enables Cosmos Health to register and sell various securities over time, providing flexible funding capacity that could be dilutive if used for primary capital raises.
Market Pulse Summary
This announcement extends COSM’s AI rollout into customer communications, echoing prior AI updates that averaged about 1.74% moves historically. Investors may watch for tangible cost savings toward the up‑to‑30% target and potential use of its $200,000,000 shelf.
Key Terms
artificial intelligence technical
multilingual voice assistant technical
outbound campaign automation technical
real-time reporting technical
AI-generated analysis. Not financial advice.
CHICAGO, June 23, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has signed an agreement to deploy an Artificial Intelligence (AI)-powered call center to support customer communications, including order intake and routine support functions, marking the latest step in the Company’s ongoing integration of AI across its operations.
Under the agreement, the Company’s wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A. (“CosmoFarm”), will deploy an AI-powered voice and communications platform to manage and enhance its customer communications. The platform is expected to support inbound and outbound calls through capabilities including a multilingual voice assistant, intelligent call handling, outbound campaign automation, integration with back-end systems, and real-time reporting and dashboards.
CosmoFarm recently reported record quarterly revenue and continued strong growth across its expanding pharmacy network. Its high and growing transaction volumes make scalable, intelligent customer engagement increasingly valuable. By automating routine customer interactions, order intake, and support functions, the AI-powered call center is expected to drive process optimization, cost efficiencies, improved responsiveness, and reduced errors, allowing CosmoFarm to continue scaling efficiently while elevating the overall customer experience.
This initiative builds on Cosmos Health’s broader AI strategy, announced in April 2026. Under that strategy, the Company has been deploying AI-driven solutions across both its front-end operations — including order management and customer relationship handling — and its back-end operations, including warehouse optimization, inventory management, and supply chain processes. In certain areas, the Company believes that AI-driven optimization may reduce specific operating expenses by up to
Greg Siokas, CEO of Cosmos Health, stated: "Deploying an AI-powered call center to support order intake and customer communications is a natural next step in our AI strategy, using technology to drive process optimization, cost efficiencies, and an improved customer experience. This is expected to deliver meaningful benefits across our operations, particularly within CosmoFarm, where record growth and a rapidly expanding customer base make intelligent automation increasingly valuable. As we continue to integrate AI across our operations, we believe we are building a more efficient, scalable, and competitive business.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
